2 news items
Cogent Biosciences Announces Part 1b Data From SUMMIT Trial Evaluating Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis; 51% Week 12 Mean Change In Total Symptom Score, Including 70% Of Patients Achieving ≥50% Reduction In TSS At Week 12
COGT
22 Feb 24
," said PD Dr. Frank Siebenhaar, M.D., Head University Outpatient Clinic, Institute of Allergology, Charité - Universitätsmedizin Berlin."We
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
COGT
22 Feb 24
of Allergology, Charité - Universitätsmedizin Berlin. "We are pleased to announce these positive results from our SUMMIT Part 1b trial
- Prev
- 1
- Next